Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma.

Key facts

Study ID

NCT00098332

Run by

BioCryst Pharmaceuticals

Starts

2004-11-01

Expected to finish

2011-07-01

Last updated by the study team

2013-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham — Birmingham, Alabama, United States
• Burke Pharmaceutical Research — Hot Springs, Arkansas, United States
• Stanford Comprehensive Cancer Center - Stanford — Stanford, California, United States
• University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Cancer and Blood Disease Center — Lecanto, Florida, United States
• Dana-Farber/Brigham and Women's Cancer Center — Boston, Massachusetts, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Charles M. Barrett Cancer Center at University Hospital — Cincinnati, Ohio, United States
• M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.